Dianthus Therapeutics (DNTH) Institutional Ownership $20.77 -1.50 (-6.74%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Dianthus Therapeutics (NASDAQ:DNTH)CurrentInstitutional OwnershipPercentage47.53%Number ofInstitutional Buyers(last 12 months)33TotalInstitutional Inflows(last 12 months)$233.03MNumber ofInstitutional Sellers(last 12 months)12TotalInstitutional Outflows(last 12 months)$29.43M Get DNTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data DNTH Institutional Buying and Selling by Quarter Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Dianthus Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC41,684$1.14M0.0%+390.5%0.141% 11/16/2024 Geode Capital Management LLC485,121$13.29M0.0%-2.8%1.639% 11/15/2024 Barclays PLC41,684$1.14M0.0%+390.5%0.141% 11/15/2024 Jane Street Group LLC20,316$556K0.0%N/A0.069% 11/15/2024 Wellington Management Group LLP53,785$1.47M0.0%N/A0.182% 11/15/2024 State Street Corp821,131$22.48M0.0%+101.4%2.774% Get the Latest News and Ratings for DNTH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 Point72 Asset Management L.P.437,700$11.98M0.0%+151.3%1.479% 11/15/2024 Janus Henderson Group PLC949,334$25.94M0.0%+40.5%3.207% 11/15/2024 HighVista Strategies LLC19,808$542K0.2%N/A0.067% 11/15/2024 Point72 Asia Singapore Pte. Ltd.8,568$235K0.0%-78.3%0.029% 11/14/2024 Fred Alger Management LLC9,633$264K0.0%+52.5%0.033% 11/14/2024 Braidwell LP493,687$13.52M0.4%+34.6%1.668% 11/14/2024 Vestal Point Capital LP395,000$10.82M0.8%-34.2%1.335% 11/14/2024 Walleye Capital LLC30,000$821K0.0%N/A0.101% 11/14/2024 MetLife Investment Management LLC13,939$382K0.0%+129.1%0.047% 11/13/2024 Great Point Partners LLC275,000$7.53M2.2%-63.7%0.929% 11/13/2024 FMR LLC4,403,148$120.56M0.0%+0.0%14.876% 11/12/2024 Charles Schwab Investment Management Inc.165,929$4.54M0.0%+142.0%0.565% 11/7/2024 Quest Partners LLC1,125$31K0.0%+112,400.0%0.004% 10/3/2024 SG Americas Securities LLC8,839$242K0.0%+104.0%0.030% 9/16/2024 Cubist Systematic Strategies LLC20,976$543K0.0%-13.1%0.071% 8/19/2024 Point72 Asset Management L.P.174,200$4.51M0.0%-50.5%0.594% 8/15/2024 The Manufacturers Life Insurance Company9,102$236K0.0%N/A0.031% 8/15/2024 Point72 Asia Singapore Pte. Ltd.39,504$1.02M0.2%+281.9%0.135% 8/14/2024 Fred Alger Management LLC6,317$163K0.0%-82.6%0.022% 8/14/2024 Cubist Systematic Strategies LLC20,976$543K0.0%-13.1%0.071% 8/14/2024 Point72 DIFC Ltd12,900$334K0.0%N/A0.044% 8/14/2024 Great Point Partners LLC757,929$19.62M3.8%+21.3%2.582% 8/14/2024 Marshall Wace LLP108,199$2.80M0.0%-4.2%0.369% 8/9/2024 Renaissance Technologies LLC88,604$2.29M0.0%-16.2%0.302% 8/9/2024 Dimensional Fund Advisors LP19,726$510K0.0%-9.2%0.067% 8/9/2024 Atlas Venture Life Science Advisors LLC136,979$3.55M0.4%-26.7%0.467% 8/9/2024 WINTON GROUP Ltd10,238$265K0.0%N/A0.035% 8/8/2024 American Century Companies Inc.30,432$788K0.0%+38.6%0.104% 8/1/2024 Rhumbline Advisers32,138$832K0.0%N/A0.109% 7/26/2024 Bank of New York Mellon Corp80,935$2.10M0.0%+860.5%0.276% 7/12/2024 SG Americas Securities LLC4,333$112K0.0%N/A0.015% 5/20/2024Virtu Financial LLC12,995$390K0.0%N/A0.044% 5/17/2024 RA Capital Management L.P.2,333,000$69.99M0.9%N/A7.949% 5/16/2024 Janus Henderson Group PLC375,044$11.25M0.0%N/A1.278% Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. 5/16/2024 Bain Capital Life Sciences Investors LLC2,992,028$89.76M7.2%N/A10.194% 5/14/2024 StemPoint Capital LP43,456$1.30M0.3%N/A0.148% 5/10/2024 Acadian Asset Management LLC4,012$120K0.0%-77.6%0.014% 5/10/2024 Vanguard Group Inc.537,828$16.14M0.0%+250.0%1.833% 5/6/2024 Atlas Venture Life Science Advisors LLC186,979$5.61M0.5%-21.1%0.637% 5/2/2024 Hussman Strategic Advisors Inc.21,000$630K0.1%N/A0.072% 2/15/2024 Octagon Capital Advisors LP554,000$5.76M0.9%+15.4%3.738% 2/14/2024 Vestal Point Capital LP135,000$1.40M0.1%N/A0.911% 2/13/2024 Tower Research Capital LLC TRC 2,430$25K0.0%N/A0.016% 12/6/2023 Citigroup Inc.3,868$53K0.0%N/A0.026% 11/15/2023 Laurion Capital Management LP36,393$497K0.0%N/A0.960% 11/14/2023 Avidity Partners Management LP1,217,554$16.64M0.7%N/A32.125% 11/13/2023 Atlas Venture Life Science Advisors LLC236,979$3.24M0.5%N/A6.249% 11/13/2023 Acadian Asset Management LLC22,299$303K0.0%N/A0.588% 11/13/2023 FMR LLC2,218,212$28.96M0.0%N/A58.497% (Data available from 1/1/2016 forward) DNTH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of DNTH shares? During the previous two years, 42 institutional investors and hedge funds held shares of Dianthus Therapeutics. The most heavily invested institutionals were FMR LLC ($120.56M), Bain Capital Life Sciences Investors LLC ($89.76M), RA Capital Management L.P. ($69.99M), Janus Henderson Group PLC ($25.94M), State Street Corp ($22.48M), Avidity Partners Management LP ($16.64M), and Vanguard Group Inc. ($16.14M).Learn more on DNTH's institutional investors. What percentage of Dianthus Therapeutics stock is owned by institutional investors? 47.53% of Dianthus Therapeutics stock is owned by institutional investors. Learn more on DNTH's institutional investor holdings. Which institutional investors have been buying Dianthus Therapeutics stock? Of the 37 institutional investors that purchased Dianthus Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($2.99M), RA Capital Management L.P. ($2.33M), FMR LLC ($2.22M), Avidity Partners Management LP ($1.22M), Janus Henderson Group PLC ($648.71K), State Street Corp ($413.43K), and Vanguard Group Inc. ($384.18K). How much institutional buying is happening at Dianthus Therapeutics? Institutional investors have bought a total of 11,802,821 shares in the last 24 months. This purchase volume represents approximately $284.04M in transactions. Which Dianthus Therapeutics major shareholders have been selling company stock? Of the 12 institutional investors that sold Dianthus Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Great Point Partners LLC ($482.93K), Vestal Point Capital LP ($205K), Point72 Asset Management L.P. ($177.90K), Atlas Venture Life Science Advisors LLC ($100K), Point72 Asia Singapore Pte. Ltd. ($30.94K), Fred Alger Management LLC ($30.05K), and Renaissance Technologies LLC ($17.10K). How much institutional selling is happening at Dianthus Therapeutics? Institutional investors have sold a total of 1,084,621 shares in the last 24 months. This volume of shares sold represents approximately $29.43M in transactions. Related Companies Amneal Pharmaceuticals Major Shareholders Scholar Rock Major Shareholders Zai Lab Major Shareholders Janux Therapeutics Major Shareholders Catalyst Pharmaceuticals Major Shareholders Iovance Biotherapeutics Major Shareholders Twist Bioscience Major Shareholders Longboard Pharmaceuticals Major Shareholders Arrowhead Pharmaceuticals Major Shareholders Protagonist Therapeutics Major Shareholders This page (NASDAQ:DNTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
